ExeGi Pharma, The makers of Visbiome Vet is focused on research and development of microbiome science and expanding the use of the De Simone Formulation contained in Visbiome® Vet in a variety of therapeutic areas. ExeGi Pharma currently has five clinical trials ongoing in additional gastrointestinal conditions of both dogs and cats.
|Disease State||Primary Endpoint||Sponsor/Collaborator||Trial Design||Estimated Enrollment|
|Intestinal inflammation and fecal dysbiosis||Canine Esomeprazole/Probiotic study (effect of probiotic admin. on fecal dysbiosis and intestinal inflam. Secondary to Esomeprazole admin in healthy dogs)||University of Wisconsin||Prospective, sequential study||14|
|Hepatic Encephalopathy||HE clinical signs and blood ammonia levels||University of Georgia||Control vs Metronidazole||20|
|Canine Epilepsy||Effect of probiotic on seizure frequency and microbiome in idiopathic epilepsy receiving anti-epileptic drugs||University of Wisconsin||Placebo-controlled, double-blinded, cross-over||30|
|Chronic Intermittent Diarrhea/evaluation of microbiome and fecal consistency in captive gibbons||Evaluate changes to the microbiome and fecal consistency over time after probiotic treatment and identify taxa that may be involved in chronic intermittent diarrhea in captive gibbons||Gibbon Conservation Center||Multi-year study||37|
If you are interested in conducting studies with Visbiome® Vet,
Let us know by filling out a short form